Coronavirus (COVID-19)
Learn more
April 27, 2017
Sponsor: National Cancer Institute (NCI)
Number: EA6134
Eligible patients who enroll in the study will be randomly assigned (by chance) to this phase III trial (Phase III: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely) which studies how well initial treatment with Ipilimumab and Nivolumab followed by Dabrafenib and Trametinib works and compares it to initial treatment with Dabrafenib and Trametinib followed by Ipilimumab and Nivolumab in treating patients with stage III-IV melanoma that contains a mutation known as BRAFV600 and cannot be removed by surgery. Stage IV is cancer which has spread from the site of the primary (original) tumor only to surrounding tissue, lymph nodes, or the development of secondary malignant growths at a distance from a primary site of cancer. Ipilimumab and Nivolumab may block tumor growth by targeting certain cells. Dabrafenib and Trametinib may block tumor growth by targeting the BRAFV600 gene. It is not yet known whether treating patients with Ipilimumab and Nivolumab followed by Dabrafenib and Trametinib is more effective than treatment with Dabrafenib and Trametinib followed by Ipilimumab and Nivolumab.
Who’s eligible:
Available at: Backus Hospital- Eastern Connecticut Hematology and Oncology.
Referral Line: 860.972.4700
Get the latest healthcare news directly in your inbox.
To receive our health news text alerts / text StartHere to 85209